In both STEP‐HFpEF (Semaglutide Treatment Effect in People with Obesity and Heart Failure with Preserved Ejection Fraction) and SUMMIT (Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity) trials, reductions in inflammatory markers (i.e. C‐reactive protein) and in N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) were observed before the peak of weight loss,11, 12, 13 contrasting with prior trials of lifestyle and dietary interventions where natriuretic peptides often increased.14 The gene discussed is NPPB; the disease is Obesity.